| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(10 years from now) | |
Camzyos is owned by Bristol.
Camzyos contains Mavacamten.
Camzyos has a total of 2 drug patents out of which 0 drug patents have expired.
Camzyos was authorised for market use on 28 April, 2022.
Camzyos is available in capsule;oral dosage forms.
Camzyos can be used as treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms.
Drug patent challenges can be filed against Camzyos from 2026-04-28.
The generics of Camzyos are possible to be released after 19 June, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 28, 2029 |
| New Chemical Entity Exclusivity (NCE) | Apr 28, 2027 |
| M (M) | Jun 15, 2026 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: 2026-04-28
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE;ORAL
CAMZYOS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic